Valeant Pharmaceuticals International Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (69)

Latest Posts

About This Stock More About This Stock
Concern Over Valeant's Financial Controls 'Likely Just Noise,' Says Cantor
Article By: The Fly
Friday, October 13, 2017 8:17 PM EDT
Cantor Fitzgerald analyst Louise Chen says after speaking with the company, she believes the concerns are "likely just noise and cannot be strung together into an argument" that Valeant has issues with financial controls.
In this article: VRX Also: DEPO
Valeant Is Thirsty For New Capital
Article By: Shock Exchange
Monday, October 2, 2017 1:38 PM EDT
VRX spooked investors last week when it filed an application to raise additional capital. Large asset impairment charges and/or legal exposures could erode the company's $4B capital base.
In this article: VRX Also: AGN, PSHZF
Valeant Attributes Today's Sell-Off To Confusion About Filing, Says Wells Fargo
Article By: The Fly
Thursday, September 28, 2017 5:47 PM EDT
Valeant Pharmaceuticals suggested the 5% intraday pullback in its shares may be related to confusion about a recent regulatory filing concerning a potential offering, Wells Fargo analyst David Maris tells investors in a research note.
In this article: VRX
Summer Sitting
Article By: Warren Bevan
Tuesday, August 8, 2017 10:48 PM EDT
The stock action is what you’d expect in August, choppy, with no direction. A few trades here and there may pop up but mostly cash seems to be best to me still.
In this article: VRX, SPY
Valeant Pharmaceuticals Q2 2017 Earnings Boost Share Price
Article By: ValueWalk
Tuesday, August 8, 2017 9:00 AM EDT
The drug maker reported adjusted earnings of $1.05 per share on $2.23 billion in revenue. Valeant said the year-over-year decline in revenues was due to lower volumes and prices in its U.S. Diversified Products segment.
In this article: VRX


Latest Tweets for $VRX

No tweets yet!